Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 8/20 | 0.44 |
| ▸ | FYN | P06241 | 4/20 | 0.41 |
| ▸ | RET | P07949 | 2/20 | 0.38 |
| ▸ | PIM2 | Q9P1W9 | 4/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | TGFBR2 | P37173 | 2/20 | 0.35 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.35 |
| ▸ | ACVR2A | P27037 | 1/20 | 0.35 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4595639 | 0.86 | PIM1 (0.60) | PIM1FYNRETPIM2 | |
| SCHEMBL4340685 | 0.85 | RET (0.46) | PIM1FYNRETPIM2 | |
| SCHEMBL4695824 | 0.85 | PIM1 (0.43) | PIM1FYNRETPIM2MAPT | |
| SCHEMBL4593820 | 0.85 | FYN (0.59) | PIM1FYNMAPTSMN1; SMN2MEN1 | |
| SCHEMBL4595026 | 0.84 | FYN (0.49) | PIM1FYNRETMAPTSMN1; SMN2 | |
| SCHEMBL4594268 | 0.84 | FYN (0.58) | PIM1FYNRETPIM2MEN1 | |
| SCHEMBL4331906 | 0.83 | FYN (0.46) | PIM1FYNRETPIM2TGFBR2 | |
| SCHEMBL4338189 | 0.83 | PIM1 (0.51) | PIM1FYNPIM2 | |
| SCHEMBL4594475 | 0.83 | CHEK1 (0.45) | PIM1FYNRETTGFBR2ACVR2A | |
| SCHEMBL4340335 | 0.82 | FYN (0.44) | PIM1FYNRETPIM2TGFBR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080039455-A1 | PYRAZOLOPYRIMIDINES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2008-02-14 | — | — | US | claimed |
| EP-1873157-A1 | Pyrazolopyrimidines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-01-02 | — | — | EP | claimed |
| US-20080039455-A1 | PYRAZOLOPYRIMIDINES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2008-02-14 | — | — | US | disclosed |
| EP-1873157-A1 | Pyrazolopyrimidines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039455-A1 | PYRAZOLOPYRIMIDINES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME | DPYD, FLT1, PDXK | PIM1 400/4885FYN 151/4885RET 911/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.